Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Epigenetic Therapy + Chemotherapy in Relapsed/Refractory AML
NCT05317403Phase 1Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Mar 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Dose-Limiting Toxicity at 42 months. Started Mar 2023; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05317403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05317403.